# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Aquestive Therapeutics released topline pharmacokinetic data for Anaphylm (epinephrine) Sublingual Film for severe allergic rea...
Anaphylm pharmacokinetic results unaffected by oral cavity exposure to liquids of different temperatures and pHRemains on track...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aquestive Therapeutics (NASDAQ:AQST) with a Buy and maintains ...
Leerink Partners analyst Roanna Ruiz initiates coverage on Aquestive Therapeutics (NASDAQ:AQST) with a Outperform rating and...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aquestive Therapeutics (NASDAQ:AQST) with a Buy and maintains ...
Cash and cash equivalents were $95.2 million as of March 31, 2024. Extended cash runway into 2026 with completion of $77.5 mill...